In January 2006, a public health advisory and boxed warning for long-term safety and the risk of malignancies and a medication guide were issued for topical calcineurin inhibitors, tacrolimus and pimecrolimus.
RESULTS: There were 57 664 eligible pediatric tacrolimus users and 425 242 eligible pediatric pimecrolimus users at baseline. The rate of TCI use decreased substantially after FDA regulatory action. The proportion of new users younger than 2 years of age significantly decreased for both tacrolimus (36.7% to 22.5%, P , .001) and pimecrolimus (47.0% to 33.7%, P , .001) after regulatory actions. Previous use of topical corticosteroids increased by ∼7% for both TCIs from the pre-to postregulatory period. However, after regulatory actions, there was only a small increase in the proportion of tacrolimus or pimecrolimus users with an atopic dermatitis or eczema diagnosis before drug initiation, and high strength use of tacrolimus was unchanged.
CONCLUSIONS:
The rate of TCI use in children younger than 2 years of age fell substantially after FDA regulatory action in 2005. Off-label use of TCI as first-line therapy changed little. One of the leading safety concerns with TCIs has been whether they might increase the risk of malignancy. During preclinical development, carcinogenicity signals were reported in both mice and monkeys. 3 Additionally, orally or intravenously administered tacrolimus is associated with an increased risk of lymphoproliferative disorders and skin cancer in transplant recipients. 4 Although TCIs are not administered systemically, systemic absorption after topical application has been reported, with increased absorption in AD resulting in greater systemic exposure. 3, 5 Systemic absorption of TCIs is of particular concern in the pediatric age group, where the ratio of body surface area to weight is greatest. This may explain why detectable blood levels of these drugs are more frequently observed in children than in adults. 3 In March 2005, the FDA issued a public health advisory warning of a potential malignancy risk with TCIs, and stated that TCIs should be used only as secondline agents, only for short periods of time, and only in children at least 2 years of age. 6 There was a general concern that TCIs were being used increasingly off-label, perhaps due in part to the heavy promotion for use in young children. 3 Supporting data revealed that from June 2003 through May 2004, the number of prescriptions dispensed for topical tacrolimus had increased by 16% and for pimecrolimus by 46%, compared with the previous year. In this same time period, patients aged 1 to 2 years accounted for 8% and 13% of topical tacrolimus and pimecrolimus prescriptions, respectively. 3 In January 2006, a boxed warning was added to TCI labeling, and a medication guide describing the potential malignancy risk with these products was issued. In March 2006, this warning was sent to prescribing physicians as a "Dear Health Care Provider" letter.
Despite heightened regulatory activity in 2005-2006, the impact of the FDA' s actions on off-label use has not been carefully evaluated in a populationbased study. The purpose of this study was to assess off-label use of TCIs in children during periods before and after the FDA' s public health advisory and boxed warning. Specifically, we sought to determine whether off-label use in children ,2 years of age and as a first-line therapy decreased after the FDA' s labeling action. The impact of the boxed warning is especially important given that on May 16, 2011, the Pediatric Advisory Committee voted to leave the existing warning given currently available data on malignancy risk. 7 
METHODS

Study Population
Through the SafeRx Project, a collaboration between the Centers for Medicare Table 1 ). The majority of users (64.3% of tacrolimus; 76.4% of pimecrolimus) did not have a diagnosis of AD or eczema during the preinitiation period. The presence of a diagnosis of psoriasis, allergic conjunctivitis, allergic rhinitis, and rash and other nonspecific skin eruptions was relatively infrequent across both cohorts. Use of topical corticosteroids before TCI initiation was low for both products (39.5% for tacrolimus; 21.2% for pimecrolimus). Mean tacrolimus refills within a year after initiation were slightly higher than mean pimecrolimus refills after initiation (tacrolimus: ,2 years, 1.75 refills; $2 years, 1.87 refills; pimecrolimus: ,2 years, 1.63 refills; $2 years, 1.62 refills). Average follow-up time ranged from 250.8 days to 296.7 days.
The rate of initiation of tacrolimus and pimecrolimus rapidly increased in children ,2 years of age within a short time after drug approval (Figs 1 and 2) . The rate of initiation of both products was higher among children ,1 year and 1 to ,2 years than among those age 2 to 19 years across the entire study period, with the exception of pimecrolimus use in children ,1 year in 2009. For both tacrolimus and pimecrolimus, rates of initiation among ,1 year and 1 to ,2 year olds followed similar patterns over time. For both age groups, the rate of tacrolimus initiation peaked in 2003/ 2004 (,1 year: 368.9 per 100 000; 1 to ,2 years: 383.5 per 100 000), and the rate of pimecrolimus initiation peaked in 2004 (,1 year: 5449.3 per 100 000; 1 to ,2 years: 4601.8 per 100 000). The rates of initiation of both products in children age ,1 year and age 1 to ,2 years dropped markedly in 2005, the year of the public health advisory, and dropped again in 2006, the year the boxed warning was issued. Rates of tacrolimus and pimecrolimus initiation among children age 2 to 19 years also Table 2 reveals the characteristics of tacrolimus and pimecrolimus use before and after regulatory action. The proportion of tacrolimus users with a previous AD or eczema diagnosis increased little after regulatory action (33.2% to 34.5%), whereas for pimecrolimus there was a slightly larger increase (20.7% to 25.8%). A sensitivity analysis using a 365-day window revealed only a small increase in the percentage of AD or eczema diagnoses (data not shown). Previous use of a topical corticosteroid increased by ∼7% for both tacrolimus and pimecrolimus from the pre-to postregulatory period. Nonetheless, during the period after regulatory actions, most children still did not receive topical corticosteroids before initiating a TCI. The proportion of users younger than 2 years of age significantly decreased for both tacrolimus (36.7% to 22.5%, P , .001) and pimecrolimus (47.0% to 33.7%, P , .001) after the regulatory actions. Of note, the contraindicated use of the higher strength tacrolimus ointment (0.03%) among children younger than age 2 years remained essentially unchanged.
DISCUSSION
We observed large decreases in the rate of new use of tacrolimus and pimecrolimus in the Medicaid pediatric population coincident with FDA regulatory actions in 2005 and 2006. In particular, there was an abrupt decrease in off-label use by children younger than 2 years of age. Although we cannot definitively attribute these decreases to specific FDA actions or publicity surrounding these actions, the decreases appear to coincide with the FDA' s public health advisory and boxed warning, which emphasized the potential risk of malignancy and that use among children younger than 2 years of age was not an approved use. 6 Although off-label TCI use in children younger than 2 years of age decreased after FDA regulatory action, the rate of use remained slightly higher than or similar to the rate observed in children .2 years. Additionally, use of the higher strength tacrolimus (0.1%) ointment among children ,2 years, which is indicated for patients .15 years only, did not change. The FDA' s regulatory actions also did not lead to a marked reduction in off-label use of these products as first-line therapies. This is particularly concerning given that this type of off-label use could result in children not receiving the most effective and safest drug in an appropriate manner. 8 Although the increase in use of topical corticosteroids before TCI initiation in the period after FDA regulatory action was statistically significant, it is likely to have negligible public health impact, with most children not being treated with them before TCI therapy initiation. The magnitude of this off-label use was greater for pimecrolimus than tacrolimus. This could be explained by varying indications for the 2 drugs with pimecrolimus indicated for mild to moderate AD and tacrolimus indicated for moderate to severe AD. There was little or no increase in the proportion of children having a diagnosis of AD or eczema before starting tacrolimus or pimecrolimus after the FDA' s regulatory action, and even then, most children did not have 1 of these diagnoses during the baseline period. Given the relatively short prior-use window of 183 days used in primary analyses, we may not have captured all diagnoses; a sensitivity analysis using a 365-day window only revealed a small increase in the percentage of AD or eczema diagnoses. Additionally, the sensitivity and the specificity of the International Classification of Diseases, Ninth Revision, Clinical Modification codes used to capture AD or eczema has not been established.
Two previous studies examined the use of TCIs in children. One study, published in abstract form only, revealed substantial declines in TCI use by children younger than the age of 2 in 2005 and again in 2007, using a pharmacy claims database. 9 The other was a crosssectional study that examined the prescription of TCIs in visits for AD by children (0-18 years) by using the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Care Survey databases. 10 The study revealed that topical tacrolimus was prescribed in 0.5 million (10%) and topical pimecrolimus was prescribed in 0.6 million (13%) of the 4.6 million AD visits in 2001 to 2004. The study also noted off-label use in children younger than 2 years, with TCIs prescribed in 22% of visits to office-based physicians or hospital outpatient departments in children younger than 2 years.
There were several important limitations to our study. Although we used a nation-wide cohort of pediatric patients from Medicaid, these differ from the general (non-Medicaid) population in terms of socioeconomic status and may carry a higher burden of medical comorbidities. Given the current AD treatment options, however, we do not expect that these differences would affect the TCI usage patterns we observed. There is also concern that the quality of medical care provided through Medicaid might be different than that available through the private sector, and that physicians who treat large numbers of Medicaid patients may differ in background and training from physicians treating privately insured patients. The potential impact of this concern on the generalizability of our results could be addressed by repeating this analysis in a privately insured population.
CONCLUSIONS
Off-label use of TCIs in children younger than 2 years of age decreased substantially in association with FDA regulatory actions, with the exception of the higher strength tacrolimus ointment. However, off-label use of TCIs as a first-line therapy in pediatric patients did not decrease and continues to remain a concern.
